Join a Perth clinical trial

A Perth clinical trial may give you access to new, innovative treatments. People who take part in a trial are often the first to access and benefit from new and emerging treatments.

We conduct clinical studies into chronic respiratory conditions, including asthma, COPD, bronchiectasis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis.

We aim to offer the best quality of care for people living with a respiratory condition

Our Unit is made up of a team of Specialists, Doctors, Registered Nurses and health science professionals. To find out if a trial is suitable for you please register with us or contact our friendly team on (08) 6457 3198. Below are some of our patient clinical trials which may be of interest to you. Click here to view our brochure for more information.

Trials Recruiting Now Closed Clinical Trials
Condition

Name

Study Outline

Eligibility & Requirements

What's Involved

Register
Asthma

Tezepelumab

The study aims to evaluate the effectiveness and safety of Tezepelumab in patients with asthma.

Aged between 18-80 with a diagnosis of asthma made by a doctor
Use of two asthma inhalers daily
At least two asthma flare-ups in the last 12 months
Current smokers excluded

You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.

Register

Bronchiectasis

Z7224L01

The study aims to evaluate the effect of inhaled colistimethate sodium (study drug) compared with no study drug on the frequency of exacerbations (chest flare ups) and the number of exacerbation-free days over the 12 month treatment period.

Aged 18 or over with a diagnosis of non-cystic fibrosis bronchiectasis by CT scan.
At least two flare ups of your bronchiectasis requiring oral antibiotic treatment in the last 12 months (or one requiring intravenous antibiotic treatment in the last 12 months).
Sputum tested positive for P. Aeuruginosa in the last 12 months.

You will be required to attend up to 7 visits to Sir Charles Gairdner Hospital and complete 2 phone calls for up to approximately 14 months.

Register

Alpha1 Antitrypsin Deficiency

GTi1201

Alpha 1 Antitrypsin Deficiency
Approximately 3 years
Phase III
Safety and Efficacy of two dose regimens of the study drug
Weekly infusions

18- 70 years old
Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema
No flare up of the chest in the last 5 weeks prior to the first visit
No cancer in last 5 years

You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
CT scans of your lungs will be required on 5 occasions throughout the trial

Register

IPF

CC-90001-IPF-001

The aim of this study is to evaluate the effect of CC-90001 in 200 mg tablet and 400 mg tablet, taken once daily compared with a placebo, on lung function after 24 weeks of treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).

Aged 40 years or older
Have been diagnosed with IPF within the last 5 years
Forced Vital Capacity (FVC) ≥45% at screening
Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and ≤ 90% predicted at Screening
Able to walk ≥150m during the 6-minute walk test at screening
(Additional inclusion/exclusion criteria apply)

You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately 26 months. In the first 6 months, you will receive study treatment or placebo (2:1) in the form of oral tablets. However, after this time you will then enter a 19-month active treatment phase where you will receive either dose of study drug. Participants will continue to receive monthly check-ups with the site’s doctor during this phase.

Register

IPF

AP01-002

A randomized open-label, phase 1b study of the safety of Pirfenidone Solution for inhalation (AP01) in patients with idiopathic pulmonary fibrosis (ATLAS Study).

40 to 90 years of age at screening.
Clinical symptoms consistent with IPF of ≥ 12 months duration (with or without IPF diagnosis).
Diagnosis of IPF, no more than 48 months before randomization.
Forced vital capacity between 40% to 90 % predicted at screening.
DLCO between 30% to 90% at screening.
Do not have a clinical diagnosis of any connective tissue disease, including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis.
Not eligible for oral pirfenidone and nintedanib due to national formulary restrictions or intolerant to or unwilling to start oral pirfenidone and nintedanib.

You will be required to attend monthly visits to Sir Charles Gairdner Hospital for approximately 6 months and then 3 monthly visits for the second part of the study (13 visits over approximately 19 months). You will receive study treatment in the form of a nebuliser (two different doses). There is no placebo in this trial.

Register

Join a Perth clinical trial

We aim to offer the best quality of care for people living with a respiratory condition

Condition

Name

Study Outline

Eligibility & Requirements

What's Involved

Register